

Potential anti-leishmanial remedies from natural sources

Zahraa S. Hadi ¹, Azal Razzaq Matrod ², Baydaa Furhan Swadi ³ and Mahdi M. Thuwaini ^{3,*}

¹ Department of Biology, College of Education for women, University of AL- Shatrah, Iraq.

² Department of Basic Sciences, College of Dentistry, Al-Ayen University, Thi qar, Iraq.

³ Department of Physiotherapy, College of Medical and Healthy Techniques, Southern Technique University, Basra, Iraq.

World Journal of Biology Pharmacy and Health Sciences, 2024, 19(02), 066–073

Publication history: Received on 23 June 2024; revised on 30 July 2024; accepted on 02 August 2024

Article DOI: <https://doi.org/10.30574/wjbphs.2024.19.2.0482>

Abstract

Leishmaniasis is caused by a protozoa parasite from over 20 *Leishmania* species. Over 90 sandfly species are known to transmit *Leishmania* parasites. There are 3 main forms of the disease, visceral (the most serious form because it is almost always fatal without treatment), cutaneous (the most common, usually causing skin ulcers), and mucocutaneous (affecting mouth, nose and throat). The disease affects some of the world's poorest people and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources. An estimated 700 000 to 1 million new cases occur annually. Chemotherapy based on the use of pentavalent antimonials, amphotericin B, paromomycin, miltefosine and liposomal amphotericin B, is currently the only effective treatment. However, adverse effects, long-term treatment and the emergence of parasite resistance have led to the search for alternative treatments. In this review, PubMed, Google Scholar, Web of Science, EBSCO, Science Direct, and Scopus were searched for medicinal plants with anti leishmanial activity to encourage identification of the active ingredients, determination of clinical efficacy, investigation of the mode of action and safety.

Keywords: Medicinal plants; Pharmacology; Antiparasitic; Anti leishmanial

1. Introduction

Parasitic diseases are one of the major public health problem⁽¹⁾. Roughly 70 protozoa species have already were infecting humans ⁽²⁾. Leishmaniasis comprises six widespread tropical diseases that are endemic in 98 countries, affecting 12 million people globally. These diseases are caused by more than 20 protozoan species of the genus *Leishmania*⁽³⁾. Three types of clinical manifestations have been reported: cutaneous, mucocutaneous and visceral leishmaniasis. The last is the most severe form; it is also known as *kala-azar* and occurs when the parasite migrates to visceral organs (especially the spleen and liver), leading to death. Chemotherapy is the most effective treatment for leishmaniasis. However, the drugs currently in use require long-term treatment, have high toxicity and are expensive and not well tolerated by patients. However, adverse effects, long-term treatment and the emergence of parasite resistance have led to the search for alternative treatments⁽⁴⁻¹¹⁾. This review discuss the plants with anti leishmanial activity to encourage further investigation of plants or plant derivatives as potential origins for novel therapies for *Leishmania* infections.

2. Medicinal plants with anti-leishmanial effects

2.1. *Achillea santolina*

Achillea santolina essential oil was investigated for *in vitro* antileishmanial activity against *Leishmania infantum* promastigote. The treatment with glucantime and *Achillea santolina* essential oil had similar efficiency with

* Corresponding author: Mahdi M. Thuwaini

the concentration of 1000 ml/mg after 72 h. The results showed that viability was significantly lower in the oil treated group⁽¹²⁻¹³⁾.

2.2. *Allium species*

Allium cepa also exerted anti-parasitic activity for many helminthes and protozoa such as, *Trichinella spiralis*, and *leishmania*⁽¹⁴⁻¹⁵⁾.

Sulfur compounds of the plant, such as Allicin, diallyl trisulphide (DAT) and ajoene can reduce developing different protozoan parasites such as *Giardia lamblia*, *Leishmania major* and *Leptomonas colosoma*⁽¹⁶⁻²¹⁾. 30 µg/mL was very efficiently inhibited the growth of other protozoan parasites such as *Giardia lamblia*, *Leishmania major*, *Leptomonas colosoma*, and *Crithidia fasciculata*⁽²²⁾.

The methanolic extract of *A. sativum* bulbs was screened for *in vitro* and *in vivo* antileishmanial activity against *Leishmania major* strain (NLB 145) and *L. donovani* strain (NLB 065). BALB/c mice and golden hamsters (*Mesocricetus auratus*) were used in *in vivo* studies of *L. major* and *L. donovani*. The extract showed IC₅₀ values of 34.22 µg/ml and 37.41 µg/ml against *L. major* and *L. donovani* promastigotes respectively, compared to 1.74 µg/ml against *L. major* and 1.18 µg/ml against *L. donovani* for Amphotericin B. The multiplication indices for *L. major* and *L. donovani* amastigotes in macrophages treated with 100 µg/ml of the extract were significantly decreased⁽²³⁾. Cytotoxic potential of *A. sativum* on *L. major* (MRHO/IR/75/ER) promastigotes was determined using the MTT assay in order to find 50% inhibitory concentration (IC₅₀) of this herbal extract. *A. sativum* showed a dose-dependent cytotoxic effect in *L. major* with almost 100% death at a concentration of 93 µg/ml⁽²⁴⁾.

2.3. *Betula alba*

Disuccinylbetulin, diglutaryldihydrobetulin, and disuccinyl dihydro betulin of *Betula alba* inhibit the growth of *Leishmania donovani*, they reduced the intracellular parasite burden in macrophages infected with wild-type *L. donovani*. They targeting enzyme type IB topoisomerase of the parasite⁽²⁵⁻²⁶⁾.

2.4. *Bryophyllum calycinum*

The antileishmanial effect of the plant extracts and its flavonoids components was evaluated *in vivo* in murine model of cutaneous leishmaniasis. Quercetin 3-O- α -L-arabinopyranosyl, α -L-rhamnopyranoside, quercetin 3-O- α -L-rhamno pyranoside and free quercetin were able to control the lesion growth caused by *Leishmania amazonensis* and significantly reduce the parasite load. These flavonoids were as effective as the crude aqueous extract which indicated that the antileishmanial effect could be attributed to flavonoids⁽²⁷⁻²⁸⁾.

2.5. *Citrullus colocynthis*

Albino mice were intraperitoneally infected with 100 X 10⁶ promastigotes of *Leishmania donovani* (MHOM/ IQ/ 982/BRCI) strain. The inoculation of albino mice caused elevation of liver and spleen weight after 7-15 days. The mice treated with 20-100 mg/kg from *Citrullus colocynthis* showed decreased average liver and spleen weight in comparison to the positive control. The most important histopathological results in the positive control included scattered necrosis, lymphatic infiltration, proliferation of macrophages and a variable number of leishman bodies were observed. 80-100 mg/kg of *Citrullus colocynthis* return liver section to normal histology⁽²⁹⁻³⁰⁾.

2.6. *Cordia myxa*

The anti-leishmanial activity of the mucilage extract of *Cordia myxa* was examined against promastigotes of *L. infantum* (MCAN/IR/96/LON49) and *L. major* (MRHO/IR/75/ER) (1×10⁶ cells/ ml). They were seeded in a 96-well microtiter plate, in the presence of the serial concentrations (0, 0.61, 1.22, 2.44, 4.88, 9.75, 19.5, 39, 78, and 156 mg/ ml w/v) of the extract and then incubated at 24°C, for 72 hours. Antileishmanial activity was assayed by light microscopy and (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) MTT method. The concentration inhibiting parasite growth by 50% (IC₅₀ value) was calculated with a sigmoid dose-response curve. Mucilage extract of *Cordia myxa* was active against promastigotes form of *L. major* and *L. infantum*, with an IC₅₀ of 26 ± 2.2 mg/ml and an IC₅₀ of 35 ± 2.2 mg/ml, respectively. The survival percentage of *L. major* and *L. infantum* promastigotes after 72 hours treatment appeared concentration dependent. Percentage of survival *Leishmania major* after 72 hours reached 17.68% in a concentration of 156 mg/ml, while the percentage of survival of *L. infantum* promastigotes after 72 hours reached 16.68% in a concentration of 156 mg/ml⁽³¹⁻³²⁾.

2.7. *Crocus sativus*

The effectiveness of *Crocus sativus* and its apoptotic activity against *Leishmania major* (MRHO/IR/ 75/ER) promastigotes was studied using MTT assay to find viability of *L. major* promastigotes and the results were explicated as IC₅₀ (50% inhibitory concentration). ED₅₀ (50% effective doses) for *L. major* amastigotes were also analyzed. Annexin-V FLUOS staining was performed to study the cell death properties of saffron by using FACS analysis. Qualitative analysis of the DNA fragmentations was accomplished by agarose gel electrophoresis, and light microscopy was used to observe morphological changes of promastigotes. The results revealed that *L. major* promastigotes and amastigotes are sensitive to saffron at different concentrations and time dependent manner, with apoptotic features including DNA laddering, cytoplasmic shrinkage, and externalization of phosphatidylserine. IC₅₀ and ED₅₀ of this extract after 48 h of incubation was 0.7 and 0.5 mg/ml respectively⁽³³⁻³⁴⁾.

2.8. *Cupressus sempervirens*

The ethanol extract of the powdered cones of *Cupressus sempervirens*, collected from Oxford, Mississippi, exhibited potent antiparasitic activities. Bioassay-guided fractionation using a centrifugal preparative thin-layer chromatography led to isolation of many diterpenes, 6-deoxytaxodione (11-hydroxy-7, 9(11), 13-abietatrien-12-one), taxodione, ferruginol and sugiol. 6-deoxytaxodione (11-hydroxy-7, 9(11), 13-abietatrien-12-one) and taxodione, displayed potent antileishmanial activity with half-maximal inhibitory concentration (IC₅₀) values of 0.077 µg/ml and 0.025 µg/ml, respectively, against *Leishmania donovani* promastigotes, compared to those of the standard antileishmanial drugs, pentamidine (IC₅₀ 1.62 µg/ml) and amphotericin B (IC₅₀ 0.11 µg/ml)⁽³⁵⁻³⁶⁾.

2.9. *Equisetum arvense*

E. arvense water extract showed anti-leishmanial effects. The number of *L. tropica* decreased gradually by using 0.5 to 2.5 µg/ml concentrations of *E. Arvense* extract. Moreover, the extracts effect on number and time of generation, an inverse relationship could be established between concentration of the extract and growth mean of the parasite. Inhibitory concentration of 50% of promastigotes (IC₅₀) was 1.5 µg/ml, whereas at logarithmic phase (96 hrs of cultivation). The *Equisetum arvense* dissolve in cold and hot water found to cause reduction in protein, carbohydrates and total nucleic acid contents in *Leishmania tropica* promastigotes that were treated with IC₅₀ of the tested extracts⁽²⁵⁷⁻²⁵⁸⁾.

2.10. *Eryngium creticum*

Antileishmanial activity of *Eryngium creticum* extract was tested *in vitro* on a culture of *Leishmania donovani* promastigotes. IC₅₀ of dichloromethane extract of the aerial parts of *Eryngium creticum* against *L. donovani* was 38µg/ml, while IC₅₀ of methanolic extract of the aerial parts of *Eryngium creticum* was 35µg/ml⁽³⁷⁻³⁸⁾.

2.11. *Eucalyptus species*

The effect of methanolic and aqueous extracts of *Eucalyptus camaldulensis* was studied on the promastigotes of *Leishmania major*. The stationary phase promastigotes of *L. major* was incubated in the methanolic and aqueous extractions *in vitro*. Tartar emetic was used as the positive control drug. After 72 h of incubation the activity of the extracts was measured, using MTT method. The IC₅₀ values were 586.2 ± 47.6 and 1,108.6 ± 51.9 µg/ml for methanolic and aqueous extracts, respectively, whereas it was 32.5 ± 6.8 µg/ml for tartar emetic⁽²⁶⁴⁾.

2.12. *Fumaria parviflora*

N-octacosan 7β ol was isolated from the methanolic extract of whole plant of *Fumaria parviflora*. The *in vitro* antileishmanial evaluation of isolated compound against *Leishmania donovani* promastigotes was investigated by growth kinetics assay, reversibility assay, analysis of cellular morphology, adverse toxicity and determination of 50% growth inhibitory concentration [GI₅₀]. N-octacosan-7β-ol [OC], possessed significant anti-*Leishmania donovani* promastigotes activity with GI₅₀ = 5.35⁽⁴³⁻⁴⁴⁾.

2.13. *Gossypium species*

The anti-leishmanial activity of methanolic extracts of *Gossypium hirsutum* was studied on *Leishmania major* promastigotes by colorimetric assay in comparison to a trivalent antimony compound (tartar emetic). The plant extracts and tartar emetic inhibited the growth of promastigote stage of *L. major* after 72 hours of incubation. Tartar emetic as positive control gave a 50% inhibitory concentration (IC₅₀) of 4.7µg/ml, while the IC₅₀ values of *G. hirsutum* was 3.6 µg/ml⁽⁴⁵⁻⁴⁶⁾.

2.14. *Hedera helix*

Saponins of ivy, *Hedera helix* possessed antileishmanial activity *in vitro* on promastigote and amastigote forms of *Leishmania infantum* and *Leishmania tropica*. Monodesmosides were found to be as effective on promastigote forms as the reference compound (pentamidine). Against amastigote forms only hederagenin exhibited a significant activity which was equivalent to that of the reference compound (N-methylglucamine antimonate)⁽⁴⁷⁾.

The *in vivo* activity of an alcoholic extract of *Hedera helix* (20% and 70% alcoholic extract) was studied in experimental ulcer of zoonotic Cutaneous leishmaniasis (CL) in Balb/c mice. The results revealed that the main lesion size did not decrease significantly, and the small lesions did not completely disappear after treatment by *H. helix* alcoholic extract. Amastigotes counts (mean \pm SD) of the skin lesions decreased in placebo control and 20% concentration groups, but in negative control and 70% concentration groups the number of parasites did not reduce⁽⁴⁸⁻⁴⁹⁾.

2.15. *Juglans regia*

The antileishmanial activity of *Juglans regia* hydroalcoholic extract was tested on the growth of the promastigotes of *Leishmania major*. The results showed that both *J. regia* extracts reduced the promastigotes number significantly ($P < 0.01$)⁽⁵⁰⁾.

The effects of topical application of the ointment-based extract (2 and 4% of 50% ethanol extract) of *Juglans regia* was studied on *Leishmania major* (MRHO/ IR/75/ ER) induced infection in mice. The results showed significant post-treatment decrease in the lesion size and parasite count in infected animals, compared to control groups⁽⁵¹⁻⁵²⁾.

2.16. *Lawsonia inermis*

The synergistic anti-leishmanial effect of *Peganum harmala* and *Lawsonia inermis* was studied using MTT assay. A significant ($p < 0.01$) inhibition of promastigotes of *L. tropica* was possessed by both extracts at low and moderate concentrations, the combined extracts revealed a synergistic inhibitory effect in comparison with each one⁽⁵³⁾.

Constituents of *Lawsonia inermis* showed antileishmanial (*Leishmania tropica*) effects. Luteolin was the most potent anti-antileishmanial compound with an IC_{50} value of 4.15 $\mu\text{g/ml}$ ⁽⁵⁴⁾.

The antileishmanial effect of *Lawsonia inermis* methanolic extracts (0.07, 0.15, 0.31, 0.62, 1.25, 2.5, 5, 10 mg/ml) was studied on *Leishmania major* promastigotes using the MTT assay. *Lawsonia inermis* methanolic extract inhibited the growth of promastigote forms of *L. major in vitro* after 72 h of incubation, and showed IC_{50} of 1.25 mg/ml⁽⁵⁵⁾.

The *in vitro* antileishmanial activity of the hydroalcoholic extract of *Lawsonia inermis* was tested on the growth of the promastigotes of *Leishmania major*. The results showed that *Lawsonia inermis* extracts reduced the promastigotes number significantly ($p < 0.01$)⁽⁵⁶⁻⁵⁷⁾.

2.17. *Lithospermum officinale*

Shikonin from *Lithospermum officinale* showed antiparasitic activity against *Culex pipiens* and *Aedes aegypti* and exhibited high toxicity for intracellular persisting *Leishmania major*⁽⁵⁸⁻⁶⁰⁾.

2.18. *Matricaria recutita*

The activity of *Matricaria chamomilla* essential oil was evaluated *in vitro* against axenic amastigotes of *Leishmania braziliensis* at concentrations lower than or equal to 250 $\mu\text{g/ml}$. The essential oil of *Matricaria chamomilla* also showed activity against intracellular amastigotes of *L. panamensis* and *L. braziliensis* (EC_{50} of 2.87 and 10.30 $\mu\text{g/ml}$, respectively⁽⁶¹⁻⁶²⁾.

2.19. *Musa paradisiaca*

The leishmanicidal activity of *Musa paradisiaca* was studied using promastigotes and amastigotes of *L. chagasi*. Two fractions of the aqueous ethanolic extract of *Musa paradisiaca* showed IC_{50} value of 1.70 and 1.83 $\mu\text{g/ml}$ against promastigotes and 14.18 and 16.54 $\mu\text{g/ml}$ against amastigotes⁽⁶³⁾.

The leishmanicidal activity of triterpenes and sterols isolated from *Musa paradisiaca* fruit peel was studied against *L. infantum chagasi* promastigotes and amastigotes. Five isolated compounds (three triterpenes: cycloeucalenone, 31-norcytolaundenone; and 24-methylene-cicloartanol and a mixture of two sterols: beta-sitosterol and stigmasterol)

showed statistically similar activity against promastigote compared to pentamidine with the exception of cycloeucalenone, furthermore, all compounds acting against amastigotes, excluding 31-norcyclolaudenone⁽⁶⁴⁻⁶⁵⁾.

2.20. *Myrtus communis*

Antileishmanial effects of essential oil and methanolic extract of *Myrtus communis* were studied on promastigote and amastigote forms of *Leishmania tropica*. Furthermore, their cytotoxic activities were investigated against J774 cells were *Myrtus communis*, particularly the essential oil, significantly ($P < 0.05$) and dose-dependently inhibited the growth rate of promastigote and amastigote forms of *L. tropica* based on a dose-dependent response. The IC_{50} values for essential oil and methanolic extract was 8.4 and 28.9 $\mu\text{g/ml}$ against promastigotes, and 11.6 and 40.8 $\mu\text{g/ml}$ against amastigote forms, respectively. The essential oil and methanolic extract possessed no significant cytotoxicity in J774 cells. However, essential oil indicated a more cytotoxic effect as compared with the methanolic extract of *Myrtus communis*⁽⁶⁶⁻⁶⁷⁾.

2.21. *Ocimum basilicum*

The antileishmanial activity of *Ocimum basilicum* leaves extract against *Leishmania tropica* was investigated. *Ocimum basilicum* showed good antileishmanial activity with LC_{50} value of 21.67 $\mu\text{g/ml}$ ⁽⁶⁸⁻⁶⁹⁾.

3. Conclusion

Natural products still play an important role in therapy, between 1981 and 2006, 1,184 new drugs were registered of which 28% were natural products or their derivatives. Several of the parasites have become resistant to chemotherapy. The chemical drugs also have many side effects, so medicinal plants can be considered as an alternative to synthetic drugs.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

- [1] Estancional CS and Marini DC. Evaluation of the frequency of intestinal parasitosis in individuals treated at a clinical analysis laboratory in the central region of Mogi Guaçu. *Foco* 2014;5(7):31-40.
- [2] Melo CR, Lira AB, Alves MF and Lima CMBL. The use of medicinal plants for parasitic diseases. *Acta Brasiliensis* 2017;1(1):28-32.
- [3] Da Silva BJM, Hage AAP, Silva EO and Rodrigues APD. Medicinal plants from the Brazilian Amazonian region and their antileishmanial activity: A review. *J Integr Med.* 2018;16(4):211-222.
- [4] Farjou IB and Al-Snafi AE. A novel treatment for hepatic hydatid cysts, combination of therapy of praziquantel or methotrexate with albendazole. *J Fac Med* 2000; 42(3): 570-578 .
- [5] Kadir MA and Al-Snafi AE. Epidemiology of scabies in Tuz district. *J Fac Med* 2000; 42(2): 321-329.
- [6] Farjou IB and Al-Snafi AE. Some protoscolicidal alternatives to formalin for *E. granulosus* hydatid cysts in man. *J Fac Med* 2001; 43(1): 81-85.
- [7] Al-Snafi AE, Kadir MA and Al-Batat HA. Evaluation of 5 days single and combined treatment of intestinal amebiasis. *J Tikrit Univ* 2001; 7(2): 158-162 .
- [8] Al-Gazi ZS, Al-Snafi AE, Al-Abady FA. Effect of toxoplasmosis and/ or its treatment (sulpadiazine and pyrimetamine) on female rats reproductive performance. *Indian Journal of Pharmaceutical Science & Research* 2016; 6(1): 35-40.
- [9] Al-Ghezy ZS, Al-Abady FA, Al-Snafi AE. Effect of toxoplasmosis and its treatments on male rats reproductive functions. *Asian Journal of Pharmaceutical Science & Technology* 2016; 6(2): 82-88.
- [10] Al-Snafi AE. Antiparasitic, antiprotozoal, molluscicidal and insecticidal activity of medicinal plants (part 2) - plant based review. *Sch Acad J Pharm* 2016; 5(6): 194-207.

- [11] Al-Snafi AE. Therapeutic properties of medicinal plants: a review of their antiparasitic, antiprotozoal, molluscicidal and insecticidal activity (part 1). *J of Pharmaceutical Biology* 2015; 5(3): 203-217.
- [12] Al-Snafi AE. Chemical constituents and pharmacological activities of Milfoil (*Achillea santolina*) - A Review. *Int J Pharm Tech Res* 2013;5(3):1373-1377.
- [13] Ayrom F, Rasouli S and Shemshadi B. *In vitro* antileishmanial activity of *Achillea santolina* essential oil against *Leishmania infantum* promastigote by methylthiazole tetrazolium (MTT) and trypan blue colorimetric methods. *Arch Razi Inst* 2021;76(3):529-536.
- [14] Guarrera PM. Traditional antihelminthic, antiparasitic and repellent uses of plants in Central Italy. *J Ethnopharmacol* 1999;68:183-192.
- [15] Al-Snafi AE. Pharmacological effects of *Allium* species grown in Iraq. An overview. *International Journal of Pharmaceutical and health care Research* 2013;1(4):132-147.
- [16] Gharadaghi Y, Shojaee S, Khaki A, Hatfeh A, Ahmadi Ashtiani HR, Rastegar H and Fathiazad F. Modulating effect of *Allium cepa* on kidney apoptosis caused by *Toxoplasma gondii*. *Adv Pharm Bull* 2012;2(1):1-6.
- [17] Anthony JP, Fyfe L, Smith H. Plant active components – a resource for antiparasitic agents. *Trends Parasitol* 2005;21(10):462-468.
- [18] Khademvatan S, Saki J, Gharavi MJ and Rahi F. *Allium sativum* extract induces apoptosis in *Leishmania major* (MRHO/IR/75/ER) promastigotes. *Journal of Medicinal Plants Research* 2011;5(16):3725-3732.
- [19] Kempinski HW. Zur kausalen Therapie chronischer Helminthen-Bronchitis. *Medizinische Klinik* 1967; 62:259-260.
- [20] Soh CT. The effects of natural food-preservative substances on the development and survival of intestinal helminth eggs and larvae. II. Action on *Ancylostoma duodenale* larvae. *American Journal of Tropical Medicine and Hygiene* 1985; 9:8-10.
- [21] Iqbal Z, Nadeem Q K, Khan M N *et al.* *In vitro* Anthelmintic Activity of *Allium sativum*, *Zingiber officinale*, *Curcubita mexicana* and *Ficus religiosa*. *International Journal of Agriculture and Biology* 2001;3(4):454-457.
- [22] Mirelman D, Monheit D and Varon S, Inhibition of growth of *Entamoeba histolytica* by Allicin, the active principle of garlic extract (*Allium sativum*). *J Infect Dis* 1987;156:243-244.
- [23] Ankri S, Miron T, Rabinkov A *et al.* Allicin from garlic strongly inhibits cysteine proteinases and cytopathic effects of *Entamoeba histolytica*, *Antimicrob Agents. Chemother* 1997;10:2286-2288.
- [24] Wabwoba BW, Anjili CO, Ngeiywa MM *et al.* Experimental chemotherapy with *Allium sativum* (Liliaceae) methanolic extract in rodents infected with *Leishmania major* and *Leishmania donovani* . *J Vector Borne Dis* 2010;47:160-167.
- [25] Chowdhury S, Mukherjee T, Sengupta S. Novel betulin derivatives as antileishmanial agents with mode of action targeting type IB DNA topoisomerase. *J Mol Pharmacol* 2009; 80(4):694-703.
- [26] Al-Snafi AE. The medical importance of *Betula alba* - An overview. *Journal of Pharmaceutical Biology* 2015;5(2):99-103.
- [27] Al-Snafi AE. The Chemical constituents and pharmacological effects of *Bryophyllum calycinum*-A review. *Journal of Pharma Sciences and Research* 2013;4(12):171-176.
- [28] Muzitano MF, Falco CAB, Cruz EA, Bergonzi MC, Bilia AR, Vincieri FF, Costa SS. Oral metabolism and efficacy of *Kalanchoe pinnata* flavonoids in a murine model cutaneous leishmaniasis. *Planta Med* 2009;75(4):307-311.
- [29] Al-Harmni KIF, Rahemo ZIF and Al-Khan HIA. The effect of two fruit extracts and drugs on the liver of albino mice with induced leishmaniasis. *Trends in Parasitology Research* 2012; 1(3): 16-26.
- [30] Al-Snafi AE. Chemical constituents and pharmacological effects of *Citrullus colocynthis* - A review. *IOSR Journal Of Pharmacy* 2016; 6(3): 57-67.
- [31] Saki J, Khademvatan S, Pazyar N, Eskandari A, Tamoradi A and Nazari P. *In vitro* activity of *Cordia myxa* mucilage extract against *Leishmania major* and *L. infantum* promastigotes. *Jundishapur J Microbiol* 2015;8(3):e19640.
- [32] Al-Snafi AE. The Pharmacological and therapeutic importance of *Cordia myxa*- A review. *IOSR Journal of Pharmacy* 2016; 6(6): 47-57.
- [33] Yousefi E, Eskandari A, Gharavi MJ and Khademvatan S. *In vitro* activity and cytotoxicity of *Crocus sativus* extract against *Leishmania major* (MRHO/IR/75/ER). *Infect Disord Drug Targets* 2014; 14(1): 56-60.

- [34] Al-Snafi AE. The pharmacology of *Crocus sativus*- A review. IOSR Journal of Pharmacy 2016; 6(6): 8-38.
- [35] Zhang J, Rahman AA, Jain S, Jacob MR, Khan SI, Tekwani BL and Ilias M. Antimicrobial and antiparasitic abietane diterpenoids from *Cupressus sempervirens*. Neuropsychiatric Disease and Treatment 2012; 2:1-6.
- [36] Al-Snafi AE. Medical importance of *Cupressus sempervirens*- A review. IOSR Journal of Pharmacy 2016; 6(6): 66-76.
- [37] Saeed BQ, Hassan HF and Arteen HI. Effect of some medical plant extracts on metabolism of *Leishmania tropica* promastigotes *in vitro*. J Med Microb Diagn 2014; 3(4): 165.
- [38] Al-Snafi AE. The pharmacology of *Equisetum arvense*- A review. IOSR Journal of Pharmacy 2017; 7(2): 31-42.
- [39] Fokialakis N, Kalpoutzakis E, Tekwani BL, Khan SI, Kobaisy M, Skaltsounis AI and Duke SO. Evaluation of the antimalarial and antileishmanial activity of plants from the Greek island of Crete. J Nat Med 2007; 61:38-45.
- [40] Al-Snafi AE. Chemical constituents and pharmacological effects of *Eryngium creticum*- A review. Indo Am J P Sci 2017; 4(01): 67-73.
- [41] Al-Snafi AE. The pharmacological and therapeutic importance of *Eucalyptus* species grown in Iraq. IOSR Journal of Pharmacy 2017; 7(3): 72-91.
- [42] Nosratabadi SJ, Sharifi I, Sharififar F, Bamorovat M, Daneshvar H and Mirzaie M. *In vitro* antileishmanial activity of methanolic and aqueous extracts of *Eucalyptus camaldulensis* against *Leishmania major*. J Parasit Dis 2015;39(1):18-21.
- [43] Al-Snafi AE. *Fumaria parviflora*- A review. Indo Am J P Sc 2018; 5(3): 1728-1738.
- [44] Hilal SH, Aboutabl EA, Youssef SAH, Shalaby MA and Sokkar NM. Lipoidal matter, flavonoid content, uterine stimulant and gonadal hormone-like activities of *Fumaria parviflora* Lam growing in Egypt. Plantae Medicinales et Phytotherapie. 1993; 26:383–396.
- [45] Al-Snafi AE. Chemical constituents and pharmacological activities of *Gossypium herbaceum* and *Gossypium hirsutum* - A review. IOSR Journal of Pharmacy 2018; 8(5): 64-80.
- [46] Barati M, Sharifi I and Sharififar F. Anti-leishmanial activity of *Artemisia aucheri*, *Ferula assafoetida* and *Gossypium hirsutum* extracts on *Leishmania major* promastigote *in vitro*. Annals of Military and Health Res 2010; 8(3): 166-172.
- [47] Majester-Savornin B, Elias R, Diaz-Lanza AM, Balansard G, Gasquet M and Delmas F. Saponins of the ivy plant, *Hedera helix*, and their leishmanicidal activity. Planta Med 1991;57(3):260-262.
- [48] Al-Snafi AE. Pharmacological and therapeutic activities of *Hedera helix*- A review IOSR Journal of Pharmacy 2018; 8(5): 41-53.
- [49] Hooshyar H, Talari S and Feyzi F. Therapeutic Effect of *Hedera helix* alcoholic extract against cutaneous leishmaniasis caused by *Leishmania major* in Balb/c Mice. Jundishapur J Microbiol 2014;7(4):e9432.
- [50] Al-Snafi AE. Chemical constituents, nutritional, pharmacological and therapeutic importance of *Juglans regia*- A review. IOSR Journal of Pharmacy 2018; 8(11): 1-21.
- [51] Serakta M, Djerrou Z, Mansour-Djaalab H, Kahlouche-Riachi F, Hamimed S, Trifa W, Belkhiri A, Edikra N and Hamdi Pacha Y. Antileishmanial activity of some plants growing in Algeria: *Juglans regia*, *Lawsonia inermis* and *Salvia officinalis*. Afr J Tradit Complement Altern Med 2013;10(3):427-430.
- [52] Chegeni AS, Ezatpour B, Mohebbali M, Mahmoudvand H, Zibaei M, Ebrahimzadeh F, Rashidipour M, Babaei N and Dokhaharani SC. Effect of peel and leaf extract of walnut (*Juglans Regia* L.) on cutaneous leishmaniasis caused by *Leishmania major* in BALB/c mice. Journal of Chemical and Pharmaceutical Sciences 2016; 9(4): 2490-2495.
- [53] Al-Snafi AE. A review on *Lawsonia inermis*: A potential medicinal plant. International Journal of Current Pharmaceutical Research 2019; 11(5):1-13.
- [54] Al-Ogaili N. Synergistic effect of *Lawsonia inermis* and *Peganum harmala* aqueous extracts on *in vitro* growth of *Leishmania tropica* promastigotes comparison to sodium stibogluconate. Al-Qadisiyah Med J 2016; 12 (22): 76-83.
- [55] Iqbal K, Iqbal J, Staerk D and Kongstad KT. Characterization of antileishmanial compounds from *Lawsonia inermis* L. leaves using semi-high resolution antileishmanial profiling combined with HPLC-HRMS-SPE-NMR. Front Pharmacol 2017;8:337.

- [56] Motazedian MH, Mikaeili F, Mohebbali M, Miri R, Habibi P and Kamarloie S. The antileishmanial effects of *Lowsonia inermis* and *Cedrus libani* on *Leishmania major* promastigotes: an *in vitro* study. *J Parasit Dis* 2017; 41(2): 375-379.
- [57] Serakta M, Djerrou Z, Mansour-Djaalab H, Kahlouche-Riachi F, Hamimed S, Trifa W, Belkhiri A, Edikra N and Hamdi Pacha Y. Antileishmanial activity of some plants growing in Algeria: *Juglans regia*, *Lawsonia inermis* and *Salvia officinalis*. *Afr J Tradit Complement Altern Med* 2013; 10(3): 427-430.
- [58] Michaelakis A, Strongilos AT, Bouzas EA, Koliopoulos G and Couladouros EA. Larvicidal activity of naturally occurring naphthoquinones and derivatives against the West Nile virus vector *Culex pipiens*. *Parasitol Res* 2009; 104: 657-662.
- [59] Al-Snafi AE. Chemical constituents and pharmacological effects of *Lithospermum officinale*. *IOSR Journal of Pharmacy* 2019; 9(8): 12-21.
- [60] Ali A, Assimopoulou AN, Papageorgiou VP and Kolodziej H. Structure/ antileishmanial activity relationship study of naphthoquinones and dependency of the mode of action on the substitution patterns. *Planta Med* 2011; 77: 2003-2012.
- [61] Al-Snafi AE and Hasham LF. Bioactive constituents and pharmacological importance of *Matricaria chamomilla*: A recent review. *GSC Biological and Pharmaceutical Sciences* 2023;22(2): 79–98.
- [62] Yesmit Karina Ríos R, Astrid Carolina Otero J, Diana Lorena Muñoz H, Mónica Echeverry R, Sara María Robledo R and Maira Alejandra Yepes C. *In vitro* leishmanicidal and cytotoxic activities of *Matricaria chamomilla* essential oil. *Rev Colomb Cienc Quím Farm* 2008; 37 (2): 200-211.
- [63] Al-Snafi AE, Talab TA, Jafari-Sales A. Nutritional and therapeutic values of *Musa paradisiaca* - A review. *Nativa, Sinop* 2023; 11(3): 396-407.
- [64] Accioly MP, Bevilaqua CM, Rondon FC, de Moraes SM, Machado LK, Almeida CA, de Andrade HF Jr and Cardoso RP. Leishmanicidal activity *in vitro* of *Musa paradisiaca* L. and *Spondias mombin* L. fractions. *Vet Parasitol* 2012;187(1-2):79-84.
- [65] Silva AA, Moraes SM, Falcão MJ, Vieira IG, Ribeiro LM, Viana SM, Teixeira MJ, Barreto FS, Carvalho CA, Cardoso RP and Andrade-Junior HF. Activity of cycloartane- type triterpenes and sterols isolated from *Musa paradisiaca* fruit peel against *Leishmania infantum* chagasi. *Phytomedicine* 2014; 21(11):1419-1423.
- [66] Al-Snaf AE, Teibo JO, Shaheen HM, Akinfe OA, Teibo TKA, Emieseimokumo N, Elfiky MM, Al-kuraishy HM, Al-Garbeeb AI, Alexiou A, Papadakis M, Mahana HAM, Younes AM, Elbanna OA, Qasem AAR, Shahin IYI, Batiha GE. The therapeutic value of *Myrtus communis* L.: an updated review. *Naunyn-Schmiedeberg's Archives of Pharmacology* 2024; <https://doi.org/10.1007/s00210-024-02958-3>
- [67] Mahmoudvand H, Ezzatkhah F, Sharififar F, Sharifi I and Dezaki ES. Antileishmanial and cytotoxic effects of essential oil and methanolic extract of *Myrtus communis* L. *Korean J Parasitol* 2015;53(1):21-27.
- [68] Khan I, Ahmad K, Khalil AT, Khan J, Khan YA, Saqib MS, Umar MN and Ahmad H. Evaluation of antileishmanial, antibacterial and brine shrimp cytotoxic potential of crude methanolic extract of herb *Ocimum basilicum* (Lamiaceae). *J Tradit Chin Med* 2015; 35(3):316-322.
- [69] Al-Snafi AE. Chemical constituents and pharmacological effects of *Ocimum basilicum*- A review. *International Journal of Pharmaceutical Research* 2021; 13(2): 2997-3013.